Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Melanie
Thomas, MD, MS, Will Serve Company as Medical Advisor
SAN ANTONIO - October 16, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, today announced that Melanie Thomas, MD, MS, a
recognized worldwide leader in the field of liver cancer, will join the company
as Medical Advisor.
Dr.
Thomas most recently held the Grace E. DeWolff Chair in Gastrointestinal
Oncology at the Medical University of South Carolina and served as Associate
Director of Clinical Investigations. As Associate Director, Dr. Thomas had
primary responsibility to oversee all clinical research infrastructure at
Hollings Cancer Center. Dr. Thomas has served as Principal Investigator on
twenty-nine separate clinical trials, primarily in gastrointestinal cancers as
well as held previous appointments at MD Anderson Cancer Center.
"Primary liver cancer (hepatocellular
carcinoma) is a very challenging disease in which to develop new, novel
therapeutic agents that are both effective and safe for patients," said
Dr. Thomas. "Hepatocellular carcinoma is a highly chemotherapy-resistant
tumor, and most patients have underlying liver damage that limits their
eligibility for clinical trials. As the third most common cancer worldwide,
hepatocellular carcinoma remains a significant unmet medical need. The early
data for mipsagargin safety and efficacy in liver cancer are impressive, and I
am excited to be part of the team that is developing this novel agent for liver
cancer patients."
"We have always actively sought the
best medical and scientific counsel in our ongoing mission to deliver
innovative therapies to cancer patients," said Craig Dionne, PhD,
GenSpera's CEO. "Dr. Thomas is a highly respected physician who brings a
wealth of clinical experience to our team. We are delighted and honored that
she has chosen to focus her efforts on the clinical development of
mipsagargin."
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/10161.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
Unlike typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an effective
approach to kill both fast- and slow-growing cancers. GenSpera's lead drug
candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high
levels in the vasculature of liver and glioblastoma cancers and in the
vasculature of almost all other solid tumors. Mipsagargin is expected to have
potential efficacy in a wide variety of tumor types.
The US Food and Drug Administration (FDA)
granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in
patients with hepatocellular carcinoma. Mipsagargin Phase II clinical trials
are underway in both hepatocellular carcinoma (liver cancer) and glioblastoma
patients (brain cancer).
For more information, please visit the
company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding
Forward Looking Information
This news release may contain
forward-looking statements. Investors are cautioned that statements in this
press release regarding potential applications of GenSpera's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results
or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties will be detailed
from time to time in GenSpera's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
+1-813-926-8920
Media: Dawn Van Zant
800-665-0411
800-665-0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:
Genspera (GNSZ) has engaged Investor Ideas for PR and news publication
effective June 18, 2014 (compensation of five thousand per month and average of
eleven thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment